Screening for colorectal cancer in the average-risk population

Seminars in Colon and Rectal Surgery

Volumn 13, Issue 1, 2002, Pages 16-30

  Kronborg, Ole ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM ENEMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CASE CONTROL STUDY; COLONOSCOPY; COLORECTAL CANCER; HUMAN; OCCULT BLOOD TEST; PHYSICAL EXAMINATION; POPULATION RISK; REVIEW; SIGMOIDOSCOPY;

EID: 0036208041     PISSN: 10431489     EISSN: None     Source Type: Journal    
DOI: 10.1053/scrs.2002.31449     Document Type: Review

References (165)

1. Case-control study of digital-rectal screening in relation to mortality from cancer of the distal rectum
2. Value of periodic examinations in detecting cancer of the rectum and colon
3. Colorectal cancer screening: Clinical guidelines and rationale
4. Screening and prevention of colorectal cancer in Haining County
5. Sigmoidoscopy in detection and diagnosis in the asymptomatic individual
6. Sigmoideoscopy in the periodic health examination of asymptomatic adults
7. The prevention of invasive cancer of the rectum
8. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer
9. Patient response to sigmoidoscopy: A randomized controlled trial of rigid and flexible sigmoidoscopy
10. Randomized trial of 'once-only' flexible sigmoidoscopy (FS) screening: Baseline results
11. Screening sigmoideoscopy and colorectal cancer mortality
12. Case-control studies of colorectal cancer mortality: Is the case made for screening sigmoidoscopy?
13. Prevention of colorectal cancer by flexible endoscopy
14. Protection by endoscopy against death from colorectal cancer
15. Population- based surveillance by colonoscopy: Effect on the incidence of colorectal cancer. Telemark Polyp Study I
16. The psychologic effect of attending a screening program for colorectal polyps
17. Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening
18. Variability in yield of neoplasia in average risk individuals undergoing flexible sigmoidoscopy (FS) screening
19. Prevention of colorectal cancer by once-only sigmoidoscopy
20. Multicentre randomised controlled trial of 'once-only' flexible sigmoidoscopy screening in Italy-score
21. The prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute
22. Repeat screening, flexible sigmoidoscopy in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial
23. Screening endoscopy and risk of colorectal cancer in United States men
24. Participation in colorectal cancer screening: A review
25. Acceptance of screening for colorectal cancer by flexible sigmoidoscopy
26. Randomized, controlled comparison of two forms of preparation for screening flexible sigmoidoscopy
27. Single blind, randomised trial of efficacy and acceptability of oral Picolax versus self administrated phosphate enema in bowel preparation for flexible sigmoidoscopy screening
28. Depth of insertion at flexible sigmoidoscopy: Implications for colorectal cancer screening and instrument design
29. Possible advantages and drawbacks of adding flexible sigmoidoscopy to Hemoccult-II in screening for colorectal cancer
30. Colorectal cancer screening: Prospective trial comparing a thinner 100 cm prototype endoscope with a standard 60 cm flexible sigmoidoscope
31. Continued change in the distribution of colorectal carcinoma
32. Distal colonic neoplasms predict proximal neoplasia in average-risk, asymptomatic subjects
33. Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy
34. Colon polyps and cancer
35. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas
36. Rectosigmoid polyps as markers of proximal colonic neoplasms: A cost benefit analysis of different diagnostic protocols
37. A UK training programme for nurse practitioner flexible sigmoidoscopy and a prospective evaluation of the practice of the first UK trained nurse flexible sigmoidoscopist
38. Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: A randomised trial
39. Screening for colorectal cancer with flexible sigmoidoscopy by non physician endoscopists
40. Efficiency and productivity of a sheathed fiberoptic sigmoidoscope compared with a conventional sigmoidoscope
41. Potential costs and benefits of once-only sigmoidoscopic screening at 60 years in an English population
42. Potential costs of flexible sigmoidoscopy-based colorectal cancer screening
43. Colonoscopy services in the United Kingdom
44. Use of colonoscopy to screen asymptomatic adults for colorectal cancer
45. Flexible sigmoidoscopy or colonoscopy as a screening modality for colorectal adenomas in older age groups? Findings in a cohort of the normal population aged 63-72 years
46. Neoplasia distal to the splenic flexure in patients with proximal colon cancer
47. Frequency of advanced neoplasia in the proximal colon without an index polyp in the rectosigmoid
48. Screening colonoscopy in asymptomatic average-risk persons with negative fecal occult blood tests
49. A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk
50. Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men
51. Bowel preparation before colonoscopy
52. Comparison of two bowel preparations for colonoscopy: Sodium picosulphate with magnesium citrate versus sulphate-free polyethylene glycol lavage solution
53. A randomized, prospective, double-blind comparison of midazolam (versed) and emulsified diazepam (Dizac) for opioid-based, conscious sedation in endoscopic procedures
54. Premedication, preparation, and surveillance
55. A new variable stiffness colonoscope makes colonoscopy easier: A randomised controlled trial
56. Appropriateness of gastrointestinal endoscopy: Risk of complications
57. Complications of diagnostic gastrointestinal endoscopy
58. Colonoscopy: A prospective report of complications
59. Colorectal cancer screening
60. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy
61. Barium enema in 1995: Where are we now?
62. The role of the barium enema in the detection of colonic neoplasms
63. Diagnostic accuracy of double-contrast enema and rectosigmoidoscopy in connection with faecal occult blood testing for the detection of rectosigmoid neoplasms
64. Colonoscopy or barium enema as initial investigation of colonic disease
65. Double-contrast barium enema and flexible sigmoidoscopy for routine colonic investigation
66. A comparison of virtual and conventional colonoscopy for the detection of colorectaI polyps
67. Diagnostic accuracy and interobserver agreement of CT colonography (virtual colonoscopy)
68. CT colonography and MR colonography: Current status, research directions and comparison
69. Virtual endoscopy - Comparison with colonoscopy in the detection of spaceoccupying lesions of the colon
70. An initial experience with screening for colon polyps using spiral CT with and without CT colography (virtual colonoscopy)
71. Reducing mortality from colorectal cancer by screening for fecal occult blood
72. Results of screening, rescreening, and follow-up in a prospective randomised study for detection of colorectal cancer by fecal occult blood testing. Results for 68.308 subjects
73. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
74. Randomised study of screening for colorectal cancer with faecal-occult-blood test
75. Effect of fecal occult blood testing on mortality from colorectal cancer
76. An evaluation of mass screening using fecal occult blood test for colorectal cancer in Japan: A case-control study
77. Zur wirk- samkeit des darmkrebs-früherkennungsprogramms. Ergebnisse einer fall-kontroll studie im Saarland
78. Effect of faecal occult blood testing on colorectal mortality: Results of a population-based case-control study in the district of Florence, Italy
79. Faecal occult blood screening and reduction of colorectal cancer mortality: A case-control study
80. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood
81. The risks of screening: Data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer
82. Survival of patients with colorectal cancer diagnosed in a randomised controlled trial of faecal occult blood screening
83. The effect of fecal occult-blood screening on the incidence of colorectal cancer
84. Faecal occult blood screening for colorectal neoplasia: A randomised trial of three days or six days of tests
85. Is dietary restriction always necessary in Haemoccult screening for colorectal neoplasia?
86. Fecal occult blood test - The importance of proper evaluation
87. Value of retesting subjects with a positive Hemoccult® in screening for colorectal cancer
88. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects
89. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test. Hemoccult
90. Double contrast barium enema and flexible rectosigmoidoscopy: A reliable diagnostic combination for detection of colorectal neoplasm
91. Review article: Faecal occult blood testing for colorectal cancer
92. Evaluation of new occult blood tests for detection of colorectal neoplasia
93. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test
94. A comparison of fecal occult-blood tests for colorectal cancer screening
95. Readability and sensitivity of a new faecal occult blood test in a hospital ward environment
96. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests
97. Screening for colorectal cancer: Alternative faecal occult blood tests
98. Five guaiac-based tests for occult blood in faeces compared in vitro and in vivo
99. The clinical value of Haemoccult and Fecatwin in the detection of colorectal neoplasia in hospital and general practice patients
100. Comparison of Coloscreen Self-test® and Haemoccult® faecal occult blood tests in the detection of colorectal cancer in symptomatic patients
101. The effect of self-administered faecal occult blood tests on compliance with screening for colorectal cancer: Results of a survey of those invited
102. Self-administered faecal occult blood tests do not increase compliance with screening for colorectal cancer: Results of a randomised controlled trial
103. Früerkennung kolorektaler karzinoma durch den nachweis von okkultem blut im stuhl mit krypto-haem SSW
104. Population screening for colorectal cancer: Comparison between guaiac and immunological faecal occult blood tests
105. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study
106. A case-control study evaluating occult blood screening for colorectal cancer with Hemoccult test and an immunochemical hemagglutination test
107. A further evaluation of the new immunochemical fecal occult blood test Flexure® obt
108. Comparative analysis of results of guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening in two oncological institutions
109. Screening for colorectal cancer with an immunological faecal occult blood test: 2 Year follow-up
110. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods
111. Screening for colorectal cancer using an immunochemical test for faecal occult blood: Results of the first 2 years of a South Australian programme
112. Assessment of the new immunological test Hemoblot for detecting occult blood in faeces
113. A comparative study of immunochemical fecal tests for detection of colorectal adenomatous polyps
114. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy
115. Immunological detection of fecal occult blood in colorectal cancer
116. Screening of colorectal tumours using an improved faecal occult blood test. Quantitative aspects
117. Fecal blood levels in health and disease. A study using HemoQuant
118. Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia
119. Evaluation and comparison of an immunochemical and a guaiac faecal occult blood screening test for colorectal neoplasia
120. Screening for colorectal neoplasms with a new immunological human faecal haemoglobin and albumin test
121. Hemoglobinhaptoglobin-complex: A highly sensitive assay for the detection of fecal occult blood
122. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces
123. Immunological determination of fecal hemoglobin and transferrin levels: A comparison with other fecal occult blood tests
124. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy
125. Critique of the early cancer detection guidelines of the US Preventive Services Task Force and of the National Cancer Institute
126. American Cancer Society Guidelines for screening and surveillance for early detection of colorectal polyps and cancer: Update 1997
127. A model to assess neoplasm detection in colon cancer screening
128. Epidemiology and early detection of colorectal cancer
129. Population based randomised study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing
130. Screening for colorectal neoplasia with faecal occult blood testing compared with flexible sigmoidoscopy directly in a 55-56 year old population
131. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening
132. Diagnostic yield of CRC in screening with once flexible sigmoidoscopy (FS) + hemoccult-II (H-II) compared to biennial H-II alone. 7th UEGW oral presentations
133. Colorectal cancer mass-screening: Estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time
134. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test
135. Interval cancers in a randomised controlled trial of screening for colorectal cancer using a faecal occult blood test
136. Screening for colorectal neoplasia
137. Fecal occult blood screening in the Minnesota Study: Sensitivity of the screening test
138. The potential role of fecal carbonic anhydrase II in screening for colorectal cancer
139. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer?
140. Faecal calprotectin levels in a high-risk population for colorectal neoplasia
141. Molecular stool screening for colorectal cancer
142. Screening for colorectal cancer. A short review
143. Noninvasive detection of colorectal cancer by molecular tools: Coming of age
144. Screening for colon cancer in Germany
145. Recommendations on cancer screening in the European Union
146. Should all people over the age of 50 have regular fecal occult-blood tests? Clinical debate
147. Controlled trial of faecal occult blood testing in the detection of colorectal cancer
148. Initial mass screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen in Denmark
149. Participation in faecal occult blood screening for colorectal cancer in a well defined French population: Results of five screening rounds from 1988 to 1996
150. Experiences of patients with false positive results from colorectal cancer screening
151. Worry associated with screening for colorectal carcinomas
152. Cost-effectiveness of colorectal cancer screening in average-risk adults
153. Screening for early colorectal cancer
154. Colorectal cancer screening: Efficiency and effectiveness
155. The relative economics of screening for colorectal cancer, breast cancer and cervical cancer
156. Screening for colorectal cancer: Present, past and future
157. Analysis of screening data: Colorectal cancer
158. Is an immunological faecal occult blood test better than Hemoccult? A cost-benefit study
159. Fecal occult blood tests. A cost-effectiveness analysis
160. An adapted program of colorectal cancer screening7 years experience and cost-benefit analysis
161. The bed-day requirement in connection with screening for colorectal cancer. Report from the first five years of a randomized population investigation
162. Screening and the costs of treating colorectal cancer
163. Cost benefit of early diagnosis of colorectal cancer